Mercator MedSystems Inc. announced Nov. 6 that the 120-patient LIMBO-ATX trial of its Bullfrog micro-infusion catheter to treat below-the-knee critical limb ischemia has completed enrollment, keeping the company on track to offer the first device that can precisely deliver drugs to below-the-knee vessels following revascularization. The firm is also looking to expand into other indications for the technology.
Bullfrog is a catheter-delivered balloon with a micro-needle that can inject therapeutic agents directly into adventitial tissue – the wall of a blood vessel. Bullfrog earned a CE mark in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?